COVID-19 Response: Development of novel COVID-19 Therapeutics utilizing Precision Medicine approach
$4,609,000.00
Grant Value
2020-21
Fiscal Year
Description
Development of a proprietary biological drug to block Coronavirus infectivity, whilst reducing induced pathology in symptomatic patients, permitting a faster recovery and avoiding multiple organ injuries
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
JN NOVA PHARMA INC
Location
Montreal, QC H3B 4W5
Agreement Details
Number: 960289
Reference: 172-2020-2021-Q3-960289
Timeline
Start: Oct. 5, 2020
End: Nov. 26, 2021
Program
Industrial Research Assistance Program ? Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (3254)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share